NEC
9.3.2020 04:02:12 CET | Business Wire | Press release
NEC Corporation (TOKYO: 6701) today announced a collaboration with Siemens in the IoT field to provide a monitoring and analysis solution for manufacturing that connects MindSphere®, the cloud-based, open Internet of Things (IoT) operating system from Siemens, and NEC's System Invariant Analysis Technology (SIAT). As part of the agreement, NEC is joining the MindSphere Partner Program, which can provide NEC with access to specialized technical training and support from Siemens as well as a number of joint go-to-market capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200308005027/en/
In recent years, with the acceleration of digitization and the spread of IoT, the safety, efficiency, maintenance and product quality of systems are being visualized and analyzed based on data collected from a large number of sensors installed in various locations, such as plant systems, manufacturing lines and factories. However, it is necessary to systemize data collection, storage, monitoring, analysis and other processes in order to utilize sensor data. Moreover, unique know-how, such as knowledge about IoT systems and data analysis, is required to construct such a system, making it difficult for customers to construct by themselves.
In addition, especially in the manufacturing industry, work processes are often based on the expertise of each plant or individual. Therefore, the loss of know-how due to the retirement of skilled personnel and lack of staff poses a serious challenge.
In order to solve these issues, NEC and Siemens have enhanced their products to enable greater visualization and analysis of sensor data.
System Invariant Analysis Technology, part of NEC's cutting-edge portfolio of AI technologies, "NEC the WISE", is being used to automatically learn and model the behavior of systems based on data gathered from a large number of sensors installed in large-scale, complex systems. This provides visualization of systems and how they operate, in addition to enabling systems to operate safely and efficiently by proactively detecting errors using analytical models. NEC has already installed approximately 100 such systems internationally.
MindSphere is the cloud-based, open IoT operating system from Siemens that connects products, plants, systems, and machines, enabling companies to harness the wealth of data generated by the IoT with advanced analytics. The MindSphere Partner Program is Siemens’ partner program for industrial IoT solution and technology providers.
This collaboration enables both companies to provide total data collection, storage, monitoring and analysis, including customization according to customer needs. Specifically, MindSphere is being used to collect and accumulate field sensor data and NEC's System Invariant Analysis Technology system automatically monitors and analyzes the data. This solution will first be offered as a cloud solution for the manufacturing industry, then applied to factory systems, manufacturing lines, plant facilities and other equipment, as well as products that are produced using this equipment. This makes it easy to visualize and analyze vast amounts of sensor data, thereby contributing to increased productivity, reduced operational risk, product quality and the preservation of know-how.
The companies plan to target customers in manufacturing industries internationally, then expand to customers in other industries.
"It is an honor to collaborate with Siemens to enhance the productivity of the manufacturing industry through System Invariant Analysis Technology,” said Osamu Fujikawa, Senior Vice President, NEC Corporation. “NEC will accelerate the digitization of enterprises through the provision of solutions worldwide that leverage both companies’ strengths. NEC will continue to address diversifying needs by fusing real and digital technologies as well as by leveraging advanced technologies such as AI and IoT,” he added.
"Siemens is committed to creating partnerships that help customers realize digital transformation with Industrial IoT. Working with NEC can help provide MindSphere applications that improve customers’ ability to add value to their digital transformation initiatives,” said Kunihiko Horita, Japan Country Manager, Siemens Digital Industries Software.
About NEC Corporation:
For more information, visit NEC at www.nec.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200308005027/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom